Mats Hardling

734 total citations
6 papers, 76 citations indexed

About

Mats Hardling is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Mats Hardling has authored 6 papers receiving a total of 76 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 3 papers in Oncology and 2 papers in Genetics. Recurrent topics in Mats Hardling's work include Chronic Myeloid Leukemia Treatments (3 papers), Acute Lymphoblastic Leukemia research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mats Hardling is often cited by papers focused on Chronic Myeloid Leukemia Treatments (3 papers), Acute Lymphoblastic Leukemia research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mats Hardling collaborates with scholars based in Sweden, United States and Denmark. Mats Hardling's co-authors include Yuan Wei, Hans Wadenvik, Anne Ricksten, Dick Stockelberg, Ulf‐Henrik Mellqvist, Bob Olsson, John Bratel, Jan‐Erik Johansson, Bengt Hasséus and Hareth Nahi and has published in prestigious journals such as Haematologica, Bone Marrow Transplantation and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Mats Hardling

6 papers receiving 74 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mats Hardling Sweden 5 44 22 20 19 19 6 76
Atsushi Marumo Japan 6 47 1.1× 12 0.5× 13 0.7× 8 0.4× 17 0.9× 20 71
Gwendolyn Van Gorkom Netherlands 8 105 2.4× 19 0.9× 21 1.1× 28 1.5× 27 1.4× 21 132
Lindsay Rein United States 7 39 0.9× 26 1.2× 16 0.8× 42 2.2× 6 0.3× 22 103
Wilma Deplano Italy 5 54 1.2× 18 0.8× 18 0.9× 16 0.8× 36 1.9× 5 76
Wilmer Flores United States 2 47 1.1× 40 1.8× 12 0.6× 14 0.7× 35 1.8× 3 73
Zaina P. Qureshi United States 4 21 0.5× 25 1.1× 32 1.6× 10 0.5× 6 0.3× 32 95
Lewis Nasr United States 9 80 1.8× 54 2.5× 29 1.4× 26 1.4× 80 4.2× 27 139
Florence Rabian France 7 44 1.0× 34 1.5× 12 0.6× 12 0.6× 12 0.6× 17 78
Aimee Jackson United Kingdom 5 41 0.9× 17 0.8× 31 1.6× 22 1.2× 11 0.6× 14 85
Habib El‐Khoury United States 6 60 1.4× 28 1.3× 21 1.1× 32 1.7× 14 0.7× 17 102

Countries citing papers authored by Mats Hardling

Since Specialization
Citations

This map shows the geographic impact of Mats Hardling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mats Hardling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mats Hardling more than expected).

Fields of papers citing papers by Mats Hardling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mats Hardling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mats Hardling. The network helps show where Mats Hardling may publish in the future.

Co-authorship network of co-authors of Mats Hardling

This figure shows the co-authorship network connecting the top 25 collaborators of Mats Hardling. A scholar is included among the top collaborators of Mats Hardling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mats Hardling. Mats Hardling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
2.
Lund, Johan, Astrid Gruber, Birgitta Lauri, et al.. (2018). Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma. Cancer Medicine. 7(6). 2256–2268. 3 indexed citations
3.
4.
Nahi, Hareth, H Hägglund, Tomas Ahlgren, et al.. (2008). An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica. 93(11). 1734–1738. 15 indexed citations
5.
Wei, Yuan, Mats Hardling, Bob Olsson, et al.. (2006). Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Annals of Hematology. 85(12). 841–847. 19 indexed citations
6.
Hardling, Mats, Yuan Wei, Lars Palmqvist, et al.. (2004). Serial Monitoring of <I>BCR-ABL</I> Transcripts in Chronic Myelogenous Leukemia (CML) Treated with Imatinib Mesylate. Medical Oncology. 21(4). 349–358. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsushi Marumo Breakdown of academic impact, for papers by Gwendolyn Van Gorkom Breakdown of academic impact, for papers by Lindsay Rein Breakdown of academic impact, for papers by Wilma Deplano Breakdown of academic impact, for papers by Wilmer Flores Breakdown of academic impact, for papers by Zaina P. Qureshi Breakdown of academic impact, for papers by Lewis Nasr Breakdown of academic impact, for papers by Florence Rabian Breakdown of academic impact, for papers by Aimee Jackson Breakdown of academic impact, for papers by Habib El‐Khoury
Rankless by CCL
2026